Between January and August 2020, the sales of veterinary drugs in the retail market amounted to RUB 14.3 bln (retail prices, VAT included), which is in monetary terms (rubles) hardly a hundredth of a percent higher than in 2019. The volume in physical terms is 125.1 bln minimum dosage units (MDU), which is 1.7% lower than in 2019.
Between January and June 2020, Russia exported RUB 23.2 bln worth of ready-made pharmaceutical drugs (customs duties included). This sum does not include Geropharm’s exports of insulins to Venezuela; while the company openly declares its exports, it does not reveal the volumes. The dynamics are +14.7% in monetary terms (rubles), which is significantly higher than those at the end of 2019 (+13%). The volume in physical terms exceeded 0.56 bln units, with the dynamics of +35%.
Between January and July 2020, Russia produced 267.1 bln RUB worth of pharmaceutical drugs (manufacturer’s prices, VAT included), which is in monetary terms (rubles) 19.4% higher than in 2019. In physical terms, the production volume is 2.78 bln units, with the dynamics of +13.3%. If calculated in minimum dosage units (MDU), the dynamics are +19%, with the volume of 48.8 bln MDUs.
The acute phase of the COVID-19 epidemic in Russia has more or less passed, to the point that the coronavirus realities have even begun to be safely forgotten. The virus obviously has affected the pharmaceutical market in general and the pharmaceutical retail in particular, especially since there are enough “concomitant diseases” in the industry as it is. The results of the second quarter of 2020 are negative, as expected, the consumers have to settle for the stocks made during the rush, and the macroeconomics also leaves much to be desired.
8/19/2020 Survey by RNC Pharma and Doktor Na Rabote (Doctor at Work): 1 in 5 Russian Doctors Ready for COVID-19 Vaccination after Industrial Production Is Launched
19% of doctors say that they will definitely get vaccinated against coronavirus after such an opportunity arises, according to a survey by the RNC Pharma analyst company and the Doktor Na Rabote (Doctor at Work) social media service for doctors. Interestingly, a significant part of those who chose to write their own answer (4%) said they refuse to vaccinate due to a previous illness.
The COVID-19 epidemic naturally became the central issue of the first half of the year. For distributors, it was a time of emergency work, a major change in both business processes and cooperation with the retail. Larger companies have long been trying to tighten relations with the retail, but the epidemic revived this trend, and made it one of the key issues in relations with partners. As a result, most of the top distributors have cut a considerable number of their delivery points. The top distributors’ share was also declining, but the factor of uneven market development was of prime importance here, since the state segment grew several times faster than the retail.
Between January and June 2020, Russia imported 6.29 bln RUB worth of veterinary vaccines (customs clearance included), which is in monetary terms (rubles) 13% higher than in 2019, even though the importers stocked up their warehouses in late 2019. The import volume of veterinary vaccines in 2019 has grown by more than 37%. In the first half of 2020, the import volume amounted to 3.39 mln units, with the dynamics of +0.4%. If calculated in dosages, the dynamics are -6.7%, and the import volume is 23.32 bln dosages.
Between January and June 2020, Russia manufactured 232 bln RUB worth of pharmaceutical drugs (manufacturers’ dispatch prices, VAT included), which is in monetary terms (rubles) 24% higher than in 2019. The dynamics in physical terms (units) are +18.3%, with the manufacture volume of 2.45 bln units. If calculated in minimum dosage units (MDU), Russia manufactured 42.7 bln MDUs, with the dynamics of +21.2%.
8/7/2020 Survey by RNC Pharma and Doktor Na Rabote (Doctor at Work): Only 11% of Russian Doctors Agree with the Official Statistics Showing Decreased Rates of COVID-19 Incidence
44% of Russian doctors believe that the COVID-19 situation is stable, but at the same time note that the morbidity rates have not significantly reduced, according to a survey by the RNC Pharma analyst company and the Doktor Na Rabote (Doctor at Work) social media service for doctors. This opinion is shared by 60% of the respondents residing in Moscow and St. Petersburg and by only 37% of those residing in the other regions. However, no one expects complete unanimity, because the epidemiological situation obviously differs from region to region.
7/31/2020 Database Update: Pharmaceutical Drug Import for Clinical Trials to Russia (June and Q1 – Q2 2020)
Between January and June 2020, Russia imported 12.2 bln RUB worth of pharmaceutical drugs for clinical trials (CT) (customs clearance and VAT included), which is in monetary terms (rubles) 49% higher than in 2019. The dynamics in physical terms (units) are also positive, +40%, with the import volume of 472 thousand units.